MedTrace Logo

Clinical Importance of Glucose Regulation in Relapsing MS

NCT03004079 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2018-11-07

No results posted yet for this study

Summary

The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery from the relapse.

Steroid exposure commonly leads to elevated serum blood glucose, however, standardized monitoring of blood glucose levels in the outpatient setting is not common. The clinical impact of any associated elevated blood glucose during steroid administration is unknown. We hypothesize that the blood glucose response to steroid treatment is clinically relevant to the MS-relapse recovery.

Conditions

  • Relapsing Remitting Multiple Sclerosis
  • Clinically Isolated Syndrome

Sponsors & Collaborators

  • National Multiple Sclerosis Society

    collaborator OTHER

  • University of Virginia

    lead OTHER

Principal Investigators

  • Myla Goldman, MD · University of Virginia

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004079 on ClinicalTrials.gov